Compare · NEOG vs QDEL
NEOG vs QDEL
Side-by-side comparison of Neogen Corporation (NEOG) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.68B, about 2.8x QDEL ($953.9M).
- Over the past year, NEOG is up 101.0% and QDEL is down 54.1% - NEOG leads by 155.1 points.
- NEOG has been more active in the news (17 items in the past 4 weeks vs 5 for QDEL).
- QDEL has more recent analyst coverage (19 ratings vs 6 for NEOG).
- Company
- Neogen Corporation
- QuidelOrtho Corporation
- Price
- $11.82-3.67%
- $12.91-6.95%
- Market cap
- $2.68B
- $953.9M
- 1M return
- -7.84%
- +16.40%
- 1Y return
- +101.02%
- -54.07%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 17
- 5
- Recent ratings
- 6
- 19
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest NEOG
- SEC Form 4 filed by Neogen Corporation
- Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
- SEC Form 10-Q filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
- Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
- NEOG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Neogen (NEOG)
- Director Woteki Catherine E was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 51% to 28,921 units (SEC Form 4)
- Director Wainer Andrea F was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 483% to 11,834 units (SEC Form 4)
Latest QDEL
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
- QuidelOrtho Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Human Resources Officer Bowman Ronald Lee converted options into 2,566 shares and covered exercise/tax liability with 921 shares, increasing direct ownership by 49% to 5,020 units (SEC Form 4) (tax withholding)
- Faster Answers, Better Decisions: ADLM 2026 Highlights
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael covered exercise/tax liability with 162 shares and converted options into 446 shares, increasing direct ownership by 4% to 8,055 units (SEC Form 4) (withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- SEC Form SCHEDULE 13G filed by QuidelOrtho Corporation